Drugs / ADP-A2M4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04408898 | Jul 2020 → Dec 2021 | head and neck cancer | Adaptimmune | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADP-A2M4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04408898 ↗ |
| Modality | Cell therapy | “autologous genetically modified ADP-A2M4” NCT04408898 ↗ |
| Route | Intravenous | “single intravenous infusion” NCT04408898 ↗ |